Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Unsuccessful trials of therapies for Alzheimer’s disease – Authors’ reply

We thank Jonathan M Schott and colleagues for their correspondence. We agree that a continuous outcome measure would be a preferable endpoint in a clinical trial compared with the discrete surrogate marker that we discuss.1 We believe that a combination of continuous outcome measures and discrete clinical state scores (ie, a composite endpoint) would increase statistical power in a clinical trial relative to any single endpoint alone, given high within-patient and between-patient variability in both types of measures.